Detalhe da pesquisa
1.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Blood
; 143(13): 1242-1258, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096363
2.
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Proc Natl Acad Sci U S A
; 116(33): 16420-16429, 2019 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371506
3.
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Blood
; 132(25): 2656-2669, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30309889
4.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Blood
; 130(22): 2401-2409, 2017 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29018077
5.
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.
BMC Cancer
; 19(1): 855, 2019 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464608
6.
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
Blood
; 128(24): 2808-2818, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697772
7.
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
Int J Mol Sci
; 19(1)2017 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29295500
8.
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
Blood
; 124(10): 1626-36, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25006124
9.
The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
BMC Cancer
; 16(1): 802, 2016 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27737650
10.
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
BMC Cancer
; 14: 437, 2014 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24927749
11.
The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.
Br J Haematol
; 180(1): 157-159, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27523575
12.
ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Blood
; 118(14): 3901-10, 2011 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-21835956
13.
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
Front Oncol
; 13: 1196005, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534243
14.
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
Br J Haematol
; 179(4): 684-688, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27471002
15.
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.
Blood Cells Mol Dis
; 48(4): 247-53, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22341562
16.
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
Haematologica
; 102(3): e112-e114, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057737
17.
Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction.
Biochem Biophys Res Commun
; 413(3): 460-4, 2011 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-21907705
18.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica
; 96(4): 574-82, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21173094
19.
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Haematologica
; 101(3): e107-10, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659917
20.
TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production.
J Immunol
; 182(7): 4471-8, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19299748